Open AccessBelantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Author(s) -
Ajay K. Nooka,
Katja Weisel,
Niels W.C.J. van de Donk,
David Routledge,
Paula Rodríguez Otero,
Kevin Song,
Hang Quach,
Natalie S. Callander,
Monique C. Minnema,
Suzanne Trudel,
Nicola Jackson,
Christoph M. Ahlers,
Ellie Im,
Shinta Cheng,
Lon Smith,
Hareth Nahi,
Geraldine FerronBrady,
Maria Brouch,
Rocío Montes de,
Sofia Paul,
Beata Holkova,
Ira Gupta,
Brandon E. Kremer,
Paul G. Richardson
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1269
Subject(s) - medicine , multiple myeloma , refractory (planetary science) , lenalidomide , oncology , clinical trial , combination therapy , pharmacology , antibody drug conjugate , pomalidomide , antibody , monoclonal antibody , immunology , physics , astrobiology
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody–drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).